EFPIA affirms strengthened commitment of industry in China with successful Beijing visit

26 September 2014

Trade group the European Federation of Pharmaceutical Industries and Associations (EFPIA) claims that there has been a strengthening of the pharma industry’s commitment in China, following a recent delegation visit to Beijing.

The purpose of the EFPIA visit was to establish a better understanding of the numerous health care reforms underway in China, share European experiences, and explore closer paths of cooperation in global drug development between China and Europe.

The EFPIA visit marks the first time a delegation of EFPIA board members, including global chief executives and EFPIA director general Richard Bergstrom, visited China. From September 25-26, a high-level EFPIA delegation, led by EFPIA president and Sanofi CEO, Chris Viehbacher, took part in a series of public events in Beijing, including a public conference on Translational Medicine in a Global World and a workshop on Transparency and Good Governance, organised together with the EU Chamber of Commerce in China. The two-day visit also included an Industry Regulatory Symposium.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK